X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs ABBOTT INDIA - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA ABBOTT INDIA SANOFI INDIA/
ABBOTT INDIA
 
P/E (TTM) x 39.4 39.1 100.7% View Chart
P/BV x 8.5 10.1 84.5% View Chart
Dividend Yield % 1.1 0.7 154.7%  

Financials

 SANOFI INDIA   ABBOTT INDIA
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
ABBOTT INDIA
Mar-18
SANOFI INDIA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs4,5606,110 74.6%   
Low Rs4,4003,996 110.1%   
Sales per share (Unadj.) Rs1,028.51,552.2 66.3%  
Earnings per share (Unadj.) Rs129.0188.8 68.3%  
Cash flow per share (Unadj.) Rs186.0196.4 94.7%  
Dividends per share (Unadj.) Rs68.0055.00 123.6%  
Dividend yield (eoy) %1.51.1 139.4%  
Book value per share (Unadj.) Rs753.6796.6 94.6%  
Shares outstanding (eoy) m23.0321.25 108.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.43.3 133.8%   
Avg P/E ratio x34.726.8 129.8%  
P/CF ratio (eoy) x24.125.7 93.6%  
Price / Book Value ratio x5.96.3 93.7%  
Dividend payout %52.729.1 181.0%   
Avg Mkt Cap Rs m103,174107,376 96.1%   
No. of employees `0003.63.3 109.1%   
Total wages/salary Rs m3,5923,937 91.2%   
Avg. sales/employee Rs Th6,537.79,929.3 65.8%   
Avg. wages/employee Rs Th991.41,185.1 83.7%   
Avg. net profit/employee Rs Th819.81,207.7 67.9%   
INCOME DATA
Net Sales Rs m23,68632,985 71.8%  
Other income Rs m7081,170 60.5%   
Total revenues Rs m24,39434,155 71.4%   
Gross profit Rs m5,2815,245 100.7%  
Depreciation Rs m1,313162 811.0%   
Interest Rs m1538 39.3%   
Profit before tax Rs m4,6616,215 75.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6912,203 76.8%   
Profit after tax Rs m2,9704,012 74.0%  
Gross profit margin %22.315.9 140.2%  
Effective tax rate %36.335.4 102.4%   
Net profit margin %12.512.2 103.1%  
BALANCE SHEET DATA
Current assets Rs m15,67322,655 69.2%   
Current liabilities Rs m6,6786,681 100.0%   
Net working cap to sales %38.048.4 78.4%  
Current ratio x2.33.4 69.2%  
Inventory Days Days7665 117.3%  
Debtors Days Days2229 76.5%  
Net fixed assets Rs m8,098835 969.3%   
Share capital Rs m230213 108.4%   
"Free" reserves Rs m17,08816,715 102.2%   
Net worth Rs m17,35616,928 102.5%   
Long term debt Rs m00-   
Total assets Rs m25,40024,162 105.1%  
Interest coverage x311.7163.7 190.4%   
Debt to equity ratio x00-  
Sales to assets ratio x0.91.4 68.3%   
Return on assets %11.816.8 70.1%  
Return on equity %17.123.7 72.2%  
Return on capital %26.936.9 72.9%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,145369 1,938.7%   
Fx outflow Rs m6,8463,807 179.8%   
Net fx Rs m299-3,438 -8.7%   
CASH FLOW
From Operations Rs m3,2261,527 211.3%  
From Investments Rs m-1,555-2,148 72.4%  
From Financial Activity Rs m-1,818-1,024 177.5%  
Net Cashflow Rs m-147-1,646 8.9%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 75.0 80.5%  
Indian inst/Mut Fund % 14.4 7.9 182.3%  
FIIs % 14.6 0.1 14,600.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.1 61.4%  
Shareholders   15,184 18,270 83.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   PIRAMAL ENTERPRISES  TORRENT PHARMA  PLETHICO PHARMA  DR. REDDYS LAB  GSK PHARMA  

Compare SANOFI INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Weak; FMCG Stocks Drag(12:30 pm)

Stock markets in India are trading in negative territory weighed by fast-moving consumer goods (FMCG) stocks.

Related Views on News

BIOCON LTD at All Time High; BSE HEALTHCARE Index Up 0.6% (Market Updates)

Sep 26, 2018 | Updated on Sep 26, 2018

BIOCON LTD share price has hit an all time high at Rs 718 (up 0.4%). The BSE HEALTHCARE Index is up by 0.6%. Among the top gainers in the BSE HEALTHCARE Index today are BIOCON LTD (up 0.4%) and DR. REDDYS LAB (up 0.3%). The top losers include APOLLO HOSPITALS and SYNGENE INTERNATIONAL .

DIVIS LABORATORIES at All Time High; BSE HEALTHCARE Index Up 1.3% (Market Updates)

Sep 26, 2018 | Updated on Sep 26, 2018

DIVIS LABORATORIES share price has hit an all time high at Rs 1,409 (up 1.5%). The BSE HEALTHCARE Index is up by 1.3%. Among the top gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 1.5%) and ABBOTT INDIA (up 0.7%). The top losers include ALEMBIC PHARMA (down 0.1%) and ERIS LIFESCIENCES LIMITED (down 0.1%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 26, 2018 01:55 PM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS